Slideshow

8 Considerations in the Differential Diagnosis of Posttraumatic Psychosis

Author(s):

Lindsey Gurin, MD,David B. Arciniegas, MD

Following TBI, cognitive deficits, comorbid medical and neurological problems, as well as complex pharmacotherapeutic needs and sensitivities frequently complicate evaluation and treatment of psychosis in this population.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
brain
nicotine use
brain schizophrenia
eating disorder brain
schizophrenia
schizophrenia
exciting, brain
Related Content
FDA Committees Vote to Dismiss Clozapine REMS
November 20th 2024

FDA Committees Vote to Dismiss Clozapine REMS

Heidi Anne Duerr, MPH
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
schizophrenia
November 18th 2024

Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment

Tracy Hicks, DNP, FNP/PMHNP-BC
What Will the Future of Alzheimer Disease Treatment Look Like?
July 23rd 2021

What Will the Future of Alzheimer Disease Treatment Look Like?

Helen Lavretsky, MD, MS
failed endpoint
November 11th 2024

Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials

Leah Kuntz
pharmacology
November 7th 2024

Schizophrenia Pharmacology: Version 2.0

John J. Miller, MD
© 2024 MJH Life Sciences

All rights reserved.